London[email protected] | 44-20-7710-7606 | v-Card | View Coverage
Max Herrmann joined Stifel in 2015. Based out of the London office, Max is an analyst in the Healthcare sector, covering Biotechnology and Pharmaceuticals. Prior to joining Stifel, he was with Oriel Securities, Silence Therapeutics Plc (as CFO), Robert Fleming Securities, ING (as head of European Pharmaceutical and Biotechnology Research), Onyx Pharmaceuticals Inc. (as financial controller), and Arthur Andersen. Max is a graduate of the University of Kent and holds a Chartered Accountant designation.